Cyber Resilience

CVE-2023-53734

HighPublic PoC

Published: 04 December 2025

Published
04 December 2025
Modified
15 April 2026
KEV Added
—
Patch
—
CVSS Score v4 8.7 CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:H/VI:N/VA:N/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
EPSS Score 0.0028 52.0th percentile
Risk Priority 18 60% EPSS · 20% KEV · 20% CVSS

Summary

CVE-2023-53734 is a high-severity SQL Injection (CWE-89) vulnerability in Mayurik (inferred from references). Its CVSS base score is 8.7 (High).

Operationally, ranked in the top 48.0% of CVEs by exploit likelihood; it is not currently listed in the CISA KEV catalog; a public proof-of-concept is referenced.

EU & UK References

Vulnerability details

dawa-pharma-1.0 allows unauthenticated attackers to execute SQL queries on the server, allowing them to access sensitive information and potentially gain administrative access.

CWE(s)
CWE-89

Related Threats

No named actor attribution yet. ATT&CK technique mapping in progress for this CVE.

Affected Assets

Mayurik
—
inferred from references and description; NVD did not file a CPE for this CVE

Mitigating Controls

Likely Mitigating Controls AI

Per-CVE control mapping for this CVE has not run yet; the list below is derived from the weakness types (CWEs) cited in the NVD entry.

CA-8 Penetration Testing
addresses: CWE-89

Penetration testing uses SQL injection payloads against database interfaces, identifying and supporting fixes for SQL injection weaknesses.

SI-10 Information Input Validation
addresses: CWE-89

Validates query inputs to prevent SQL syntax or command manipulation.

References